CAS |
No.614749-78-9 |
英文名称 |
SM 16 |
分子式 |
C25H26N4O3 |
分子量 |
430.5 |
溶解性 |
Soluble in DMSO ≥5mg/mL |
纯度 |
≥98% |
外观(性状) |
White to off-white Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
运输条件 |
冷藏运输 |
靶点 |
ALK4/5 |
通路 |
TGF-beta/Smad |
背景说明 |
SM 16 是 ALK5/ALK4 激酶抑制剂。 |
生物活性 |
SM 16 is a ALK5/ALK4 kinase inhibitor with Kis of 10 and 1.5 nM, respectively.[1-3] |
IC50 |
Ki: ALK5 (10 nM), ALK4 (1.5 nM)[1] |
In Vitro |
SM 16 在浓度为 100 到 620 nM 时抑制 TGFβ 诱导的纤溶酶原激活剂抑制剂-荧光素酶活性 (IC50=64 nM) 和 TGFβ-或激活素诱导的 Smad2 磷酸化。SM 16 针对 >60 种相关和无关激酶进行了测试,仅针对 Raf (IC50=1 μM) 和 p38/SAPKa (IC50= 0.8 μM)。SM 16 对 ALK 家族成员 ALK1 和 ALK6 没有抑制活性[1]。 |
In Vivo |
SM 16 体内 穿透肿瘤细胞,在用 20 mg/kg SM 16 单次腹腔推注处理荷瘤小鼠后抑制肿瘤磷酸化 Smad2/3 水平至少 3 小时。已建立的 AB12 肿瘤在 28 天内通过皮下微渗透泵递送 5 mg/kg/d SM 16 (P[1]。 |
动物实验 |
Mice[1]BALB/c mice are injected on the right flank with 1×106 AB12 tumor cells. Mice are randomly divided into two groups and one group is implanted with minipumps loaded with 20% Captisol (control) on the left flank and the other group is implanted with minipumps loaded with 20 mg/mL SM 16. Tumor recurrence is defined as the first day when a tumor is unambiguously visible or palpable. Plasma is obtained under anesthesia and analyzed for SM 16[1]. |
数据来源文献 |
[1]. Suzuki E, et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007 Mar 1;67(5):2351-9. [2]. Fu K, et al. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):665-71. [3]. Engebretsen KV, et al. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. J Mol Cell Cardiol. 2014 Nov;76:148-57. |
规格 |
1mg 5mg 10mg 50mg 100mg |
单位 |
瓶 |